Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCND3 | P30281 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24907425 | 0.75 | — | — | |
| SCHEMBL18156042 | 0.74 | ACHE (0.38) | ROCK1ACHEHCRTR1HCRTR2 | |
| SCHEMBL10249223 | 0.73 | EPHB4 (0.43) | — | |
| SCHEMBL13494687 | 0.72 | L3MBTL1 (0.33) | — | |
| SCHEMBL11918420 | 0.71 | AR (0.38) | LRRK2ACHE | |
| SCHEMBL611806 | 0.71 | MAPT (0.47) | LRRK2ROCK1ACHE | |
| SCHEMBL26771957 | 0.71 | LRRK2 (0.35) | LRRK2ROCK1ACHEHCRTR1HCRTR2 | |
| SCHEMBL23022219 | 0.71 | EPHX2 (0.37) | LRRK2ROCK1ACHENAMPTHCRTR1 | |
| SCHEMBL671951 | 0.71 | ALDH1A1 (0.43) | LRRK2ROCK1 | |
| SCHEMBL2378629 | 0.71 | AR (0.38) | LRRK2ROCK1ACHENAMPTHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| CN-106459051-B | Macrocyclic FXIA Inhibitors Containing Heterocyclic Groups | 百时美施贵宝公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-102498110-A | 2- (LH-pyrazol-4-ylamino) -pyrimidine as kinase inhibitors | ABBOTT LAB | 2012-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DPYD, TYMP, TYMS | LRRK2 1579/4885ROCK1 4273/4885ACHE 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.